Esperion Therapeutics, Inc.
ESPREsperion Therapeutics, Inc. (ESPR) is a pharmaceutical company focused on developing and commercializing oral lipid-lowering medicines to treat patients with high cholesterol and related cardiovascular conditions. Founded in 2008, the company specializes in therapies targeting elevated LDL cholesterol through innovative oral agents, aiming to provide additional options for patients who require more effective lipid management.
Company News
Esperion announced positive Phase 2 pediatric study results showing bempedoic acid (NEXLETOL) safely reduced LDL-C by 6-25% in children aged 6-17 with familial hypercholesterolemia. Additionally, a secondary analysis of CLEAR Outcomes found that 42% of statin-intolerant patients achieved ≥30% LDL-C reduction at 3 months, with enhanced results i...
Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential violations of federal securities laws and breaches of fiduciary duties. The investigations concern Sila Realty Trust's sale to Blue Owl affiliates, Esperion Therapeutics' sale to ARCHIMED funds, and a merger between Corebridge Financial and Equitable Hold...
Law firm Brodsky & Smith announced investigations into four merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and ensure fair value for shareholders. The investigations involve Esperion Therapeutics (ARCHIMED acquisition at $3.16/share), Sila Realty Trust (Blue Owl Capital acquisi...
Esperion Therapeutics (ESPR) shares rose on Monday following announcement of a $1.1 billion acquisition deal with Archimed. Shareholders will receive $3.16 per share in cash plus contingent value rights (CVRs) representing a 58% premium to the April 30 closing price. The CVRs include potential milestone payments up to $100 million based on future...
Monteverde & Associates PC is investigating Esperion Therapeutics' proposed sale to ARCHIMED funds, where shareholders would receive $3.16 per share in cash plus contingent milestone payments. The investigation questions whether the deal terms are fair to shareholders.
